Weight loss injection pens contain GLP-1 receptor agonist medications, such as semaglutide — a clinically proven option for weight management. Research shows that individuals may lose an average of 15% of their body weight, with about 30–35% losing 20% or more. Semaglutide has also been shown to lower the risk of heart attacks and strokes, particularly in people who are overweight or obese and have existing cardiovascular risk factors.
Semaglutide mimics a natural hormone in the body known as GLP-1, which influences appetite and digestion.
Evidence suggests that weight may return once the medication is stopped. For sustained results, long-term use may be recommended.